Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
202 stocks in the Americas match these filters · market cap, largest first. Clear filters
Data as of Aug 27, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| MNPR | Monopar Therapeutics Inc. | Oncology | $763.31M | $113.72 | −8.89% | +4.24% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | Oncology | $751.23M | $9.26 | −37.73% | +7.80% |
| CTMX | CytomX Therapeutics, Inc. | Oncology | $723.43M | $3.32 | −59.56% | +3.11% |
| GUD.TO | Knight Therapeutics Inc. |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| Oncology |
| $690.78M |
| 9.76 CAD |
| −4.03% |
| −0.81% |
| EIKN | Eikon Therapeutics, Inc. | Oncology | $679.77M | $11.98 | −31.15% | +26.24% |
| SGMT | Sagimet Biosciences Inc. | Oncology | $675.04M | $10.86 | −2.60% | +49.38% |
| CBIO | Crescent Biopharma, Inc. | Oncology | $669.39M | $18.02 | −34.26% | +9.61% |
| VSTM | Verastem, Inc. | Oncology | $641.19M | $7.39 | −34.31% | +18.62% |
| ARVN | Arvinas, Inc. | Oncology | $609.40M | $9.32 | −35.77% | +13.66% |
| DCTH | Delcath Systems, Inc. | Oncology | $569.06M | $16.40 | −5.86% | +41.99% |
| PRLD | Prelude Therapeutics Incorporated | Oncology | $522.47M | $6.56 | −3.95% | +41.38% |
| CCCC | C4 Therapeutics, Inc. | Oncology | $521.63M | $4.24 | −17.99% | +19.44% |
| TOI | Starling Oncology Inc | Oncology | $512.91M | $6.20 | −12.06% | +25.25% |
| RLMD | Relmada Therapeutics, Inc. | Oncology | $485.35M | $4.55 | −43.13% | −13.00% |
| PBYI | Puma Biotechnology, Inc. | Oncology | $472.84M | $9.16 | −3.68% | +14.93% |
| CMPX | Compass Therapeutics, Inc. | Oncology | $437.61M | $2.43 | −64.68% | +19.12% |
| FRX.TO | Fennec Pharmaceuticals Inc. | Oncology | $429.52M | 17.00 CAD | −3.63% | +21.86% |
| FENC | Fennec Pharmaceuticals Inc. | Oncology | $426.77M | $12.17 | −8.15% | +22.43% |
| GALT | Galectin Therapeutics Inc. | Oncology | $418.53M | $4.15 | −41.80% | +22.42% |
| FHTX | Foghorn Therapeutics Inc. | Oncology | $397.29M | $6.69 | −12.09% | +30.41% |
| AGEN | Agenus Inc. | Oncology | $371.33M | $8.25 | −6.78% | +25.00% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Oncology | $368.27M | $3.89 | −44.03% | −15.80% |
| CATX | Perspective Therapeutics, Inc. | Oncology | $360.72M | $3.16 | −48.70% | +10.10% |
| STRO | Sutro Biopharma, Inc. | Oncology | $355.50M | $21.43 | −51.13% | −9.69% |
| IMRX | Immuneering Corporation | Oncology | $333.19M | $5.15 | −48.91% | +21.46% |
| BCYC | Bicycle Therapeutics plc | Oncology | $304.03M | $4.36 | −52.45% | +10.53% |
| PYXS | Pyxis Oncology, Inc. | Oncology | $278.58M | $3.34 | −39.82% | +14.78% |
| WHWK | Whitehawk Therapeutics, Inc. | Oncology | $275.92M | $4.84 | −11.92% | +31.52% |
| ALXO | ALX Oncology Holdings Inc. | Oncology | $273.79M | $1.98 | −25.56% | −0.50% |
| CGEN | Compugen Ltd. | Oncology | $271.86M | $2.84 | −12.35% | +25.66% |
| GLSI | Greenwich LifeSciences, Inc. | Oncology | $267.58M | $18.23 | −46.54% | +35.54% |
| ADAG | Adagene Inc. | Oncology | $258.50M | $3.85 | −20.62% | +3.22% |
| MGNX | MacroGenics, Inc. Common Stock | Oncology | $257.35M | $4.04 | −20.47% | +4.94% |
| IPHA | Innate Pharma S.A. | Oncology | $253.56M | $2.16 | −20.30% | +28.57% |
| TARA | Protara Therapeutics, Inc. | Oncology | $231.06M | $3.91 | −50.00% | −0.76% |
| CHRS | Coherus Oncology, Inc. | Oncology | $224.03M | $1.45 | −44.57% | +0.69% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | Oncology | $218.56M | $11.30 | −45.04% | +24.38% |
| NBP | NovaBridge Biosciences | Oncology | $216.26M | $1.87 | −72.46% | +6.86% |
| CUE | Cue Biopharma, Inc. | Oncology | $209.58M | $28.85 | −36.59% | −4.63% |
| MOLN | Molecular Partners AG | Oncology | $170.46M | $4.45 | −16.98% | +16.19% |
| MENS | Jyong Biotech Ltd. | Oncology | $170.30M | $2.24 | −96.66% | −6.28% |
| KZIA | Kazia Therapeutics Limited | Oncology | $166.83M | $14.60 | −16.09% | +15.05% |
| OKUR | OnKure Therapeutics, Inc. | Oncology | $155.52M | $3.80 | −29.37% | −3.80% |
| ASRT | Assertio Holdings Inc | Oncology | $151.86M | $23.50 | 0.00% | 0.00% |
| INDP | Indaptus Therapeutics, Inc. | Oncology | $145.90M | $1.14 | −86.70% | −34.10% |
| HURA | TuHURA Biosciences, Inc. | Oncology | $135.74M | $2.13 | −37.90% | 0.00% |
| ADCT | ADC Therapeutics SA | Oncology | $134.05M | $1.05 | −78.92% | −5.41% |
| BDTX | Black Diamond Therapeutics, Inc. | Oncology | $130.42M | $2.27 | −54.05% | +28.98% |
| LIXT | Nomad Power Solutions Inc | Oncology | $125.36M | $4.18 | −50.12% | −5.64% |
| GNLX | Genelux Corporation | Oncology | $123.52M | $2.73 | −68.01% | −6.51% |
| ANIX | Anixa Biosciences, Inc. | Oncology | $122.65M | $3.61 | −33.97% | +2.41% |
| NTHI | NeOnc Technologies Holdings, Inc. | Oncology | $122.16M | $4.56 | −64.90% | +30.66% |
| ONCY | Oncolytics Biotech Inc. | Oncology | $109.10M | $0.86 | −43.34% | +8.30% |
| HBP.TO | Helix BioPharma Corp. | Oncology | $106.76M | 1.94 CAD | −64.07% | +33.79% |
| AMAN | Amanat Acquisition Corp | Oncology | $103.52M | $10.70 | −0.47% | +5.42% |
| JATT | JATT II Acquisition Corp. | Oncology | $93.68M | $12.01 | −49.45% | +7.81% |
| ACRV | Acrivon Therapeutics, Inc. | Oncology | $93.42M | $2.08 | −41.57% | +35.06% |
| MAIA | MAIA Biotechnology, Inc. | Oncology | $84.56M | $1.39 | −56.43% | +12.10% |
| VRCA | Verrica Pharmaceuticals Inc. | Oncology | $84.35M | $4.91 | −50.01% | −9.07% |
| CTOR | Citius Oncology, Inc. | Oncology | $83.24M | $0.79 | −65.02% | +45.49% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.